• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

构建免疫相关特征并鉴定 S100A14 以确定胰腺癌中的免疫抑制微环境。

Construction of immune-related signature and identification of S100A14 determining immune-suppressive microenvironment in pancreatic cancer.

机构信息

Department of General Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100023, PR China.

出版信息

BMC Cancer. 2022 Aug 11;22(1):879. doi: 10.1186/s12885-022-09927-0.

DOI:10.1186/s12885-022-09927-0
PMID:35953822
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9367131/
Abstract

Pancreatic cancer (PC) is a highly lethal and aggressive disease with its incidence and mortality quite discouraging. A robust prognostic signature and novel biomarkers are urgently needed for accurate stratification of the patients and optimization of clinical decision-making. Since the critical role of immune microenvironment in the progression of PC, a prognostic signature based on seven immune-related genes was established, which was validated in The Cancer Genome Atlas (TCGA) training set, TCGA testing set, TCGA entire set and GSE71729 set. Furthermore, S100A14 (S100 Calcium Binding Protein A14) was identified as the gene occupying the most paramount position in risk signature. According to the GSEA, CIBERSORT and ESTIMATE algorithm, S100A14 was mainly associated with lower proportion of CD8 + T cells and higher proportion of M0 macrophages in PC tissue. Meanwhile, analysis of single-cell dataset CRA001160 revealed a significant negative correlation between S100A14 expression in PC cells and CD8 + T cell infiltration, which was further confirmed by tissue microenvironment landscape imaging and machine learning-based analysis in our own PUMCH cohort. Additionally, analysis of a pan-pancreatic cancer cell line illustrated that S100A14 might inhibit CD8 + T cell activation via the upregulation of PD-L1 expression in PC cells, which was also verified by the immunohistochemical results of PUMCH cohort. Finally, tumor mutation burden analysis and immunophenoscore algorithm revealed that patients with high S100A14 expression had a higher probability of responding to immunotherapy. In conclusion, our study established an efficient immune-related prediction model and identified the potential role of S100A14 in regulating the immune microenvironment and serving as a biomarker for immunotherapy efficacy prediction.

摘要

胰腺癌(PC)是一种高度致命和侵袭性的疾病,其发病率和死亡率相当令人沮丧。迫切需要建立一个稳健的预后标志物和新的生物标志物,以便对患者进行准确分层和优化临床决策。由于免疫微环境在 PC 进展中的关键作用,建立了一个基于七个免疫相关基因的预后标志物,在 TCGA 训练集、TCGA 测试集、TCGA 全集中和 GSE71729 集中进行了验证。此外,S100A14(S100 钙结合蛋白 A14)被鉴定为风险标志物中占据最重要位置的基因。根据 GSEA、CIBERSORT 和 ESTIMATE 算法,S100A14 主要与 PC 组织中 CD8+T 细胞比例较低和 M0 巨噬细胞比例较高相关。同时,对单细胞数据集 CRA001160 的分析表明,S100A14 在 PC 细胞中的表达与 CD8+T 细胞浸润呈显著负相关,这在我们自己的 PUMCH 队列的组织微环境景观成像和基于机器学习的分析中得到了进一步证实。此外,对泛胰腺癌细胞系的分析表明,S100A14 可能通过上调 PC 细胞中 PD-L1 的表达来抑制 CD8+T 细胞的激活,这在 PUMCH 队列的免疫组化结果中也得到了验证。最后,肿瘤突变负担分析和免疫表型评分算法表明,S100A14 表达较高的患者对免疫治疗的反应可能性更高。总之,我们的研究建立了一个有效的免疫相关预测模型,并确定了 S100A14 在调节免疫微环境和作为免疫治疗疗效预测生物标志物方面的潜在作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2600/9367131/7f838eb69448/12885_2022_9927_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2600/9367131/590e46c85f66/12885_2022_9927_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2600/9367131/ac35db4931b3/12885_2022_9927_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2600/9367131/ab03dc746747/12885_2022_9927_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2600/9367131/7d77e28b9fb9/12885_2022_9927_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2600/9367131/5ad8cf1925c5/12885_2022_9927_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2600/9367131/9cc3aaf8779b/12885_2022_9927_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2600/9367131/3b91ecaa1a03/12885_2022_9927_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2600/9367131/cbaabb98876c/12885_2022_9927_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2600/9367131/7f838eb69448/12885_2022_9927_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2600/9367131/590e46c85f66/12885_2022_9927_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2600/9367131/ac35db4931b3/12885_2022_9927_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2600/9367131/ab03dc746747/12885_2022_9927_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2600/9367131/7d77e28b9fb9/12885_2022_9927_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2600/9367131/5ad8cf1925c5/12885_2022_9927_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2600/9367131/9cc3aaf8779b/12885_2022_9927_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2600/9367131/3b91ecaa1a03/12885_2022_9927_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2600/9367131/cbaabb98876c/12885_2022_9927_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2600/9367131/7f838eb69448/12885_2022_9927_Fig9_HTML.jpg

相似文献

1
Construction of immune-related signature and identification of S100A14 determining immune-suppressive microenvironment in pancreatic cancer.构建免疫相关特征并鉴定 S100A14 以确定胰腺癌中的免疫抑制微环境。
BMC Cancer. 2022 Aug 11;22(1):879. doi: 10.1186/s12885-022-09927-0.
2
S100A2 Is a Prognostic Biomarker Involved in Immune Infiltration and Predict Immunotherapy Response in Pancreatic Cancer.S100A2 是一种预后生物标志物,参与胰腺癌的免疫浸润并预测免疫治疗反应。
Front Immunol. 2021 Nov 23;12:758004. doi: 10.3389/fimmu.2021.758004. eCollection 2021.
3
Immune-related signature identifies IL1R2 as an immunological and prognostic biomarker in pancreatic cancer.免疫相关特征将白细胞介素1受体2鉴定为胰腺癌的免疫和预后生物标志物。
J Pancreatol. 2024 Jun;7(2):119-130. doi: 10.1097/JP9.0000000000000175. Epub 2024 Feb 22.
4
Up-regulation of S100P predicts the poor long-term survival and construction of prognostic signature for survival and immunotherapy in patients with pancreatic cancer.S100P 的上调预示着胰腺癌患者长期生存不良,并构建了用于生存和免疫治疗的预后特征。
Bioengineered. 2021 Dec;12(1):9006-9020. doi: 10.1080/21655979.2021.1992331.
5
Identification of the immune cell infiltration landscape in pancreatic cancer to assist immunotherapy.鉴定胰腺癌中的免疫细胞浸润图谱以辅助免疫治疗。
Future Oncol. 2021 Nov;17(31):4131-4143. doi: 10.2217/fon-2021-0495. Epub 2021 Aug 4.
6
A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.一种基于放射组学的方法来评估肿瘤浸润 CD8 细胞与抗 PD-1 或抗 PD-L1 免疫治疗反应的关系:一项影像学生物标志物、回顾性多队列研究。
Lancet Oncol. 2018 Sep;19(9):1180-1191. doi: 10.1016/S1470-2045(18)30413-3. Epub 2018 Aug 14.
7
A DNA-Methylation-Driven Genes Based Prognostic Signature Reveals Immune Microenvironment in Pancreatic Cancer.基于 DNA 甲基化驱动基因的预后标志物揭示了胰腺癌中的免疫微环境。
Front Immunol. 2022 Feb 10;13:803962. doi: 10.3389/fimmu.2022.803962. eCollection 2022.
8
Identifying and Validating an Acidosis-Related Signature Associated with Prognosis and Tumor Immune Infiltration Characteristics in Pancreatic Carcinoma.识别和验证与胰腺癌预后和肿瘤免疫浸润特征相关的酸中毒相关特征。
J Immunol Res. 2021 Dec 28;2021:3821055. doi: 10.1155/2021/3821055. eCollection 2021.
9
Identification of tumour immune microenvironment-related alternative splicing events for the prognostication of pancreatic adenocarcinoma.鉴定肿瘤免疫微环境相关的可变剪接事件,用于预测胰腺腺癌的预后。
BMC Cancer. 2021 Nov 12;21(1):1211. doi: 10.1186/s12885-021-08962-7.
10
Construction of a novel model based on cell-in-cell-related genes and validation of KRT7 as a biomarker for predicting survival and immune microenvironment in pancreatic cancer.构建基于细胞内相关基因的新型模型,并验证 KRT7 作为预测胰腺癌患者生存和免疫微环境的标志物。
BMC Cancer. 2022 Aug 16;22(1):894. doi: 10.1186/s12885-022-09983-6.

引用本文的文献

1
The immune-related prognostic gene AIM2 promotes pancreatic cancer progression via inflammasome.免疫相关预后基因AIM2通过炎性小体促进胰腺癌进展。
Sci Rep. 2025 Aug 13;15(1):29733. doi: 10.1038/s41598-025-12651-x.
2
Establishment and validation of an immune-related nomogram for the prognosis of pancreatic adenocarcinoma.用于预测胰腺腺癌预后的免疫相关列线图的建立与验证
Sci Rep. 2025 Apr 18;15(1):13431. doi: 10.1038/s41598-025-98503-0.
3
Machine learning‑based construction of damage‑associated molecular patterns related score identifies subtypes of pancreatic adenocarcinoma with distinct prognosis.

本文引用的文献

1
Cancer statistics, 2022.癌症统计数据,2022 年。
CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12.
2
S100A2 Is a Prognostic Biomarker Involved in Immune Infiltration and Predict Immunotherapy Response in Pancreatic Cancer.S100A2 是一种预后生物标志物,参与胰腺癌的免疫浸润并预测免疫治疗反应。
Front Immunol. 2021 Nov 23;12:758004. doi: 10.3389/fimmu.2021.758004. eCollection 2021.
3
Proteogenomic characterization of pancreatic ductal adenocarcinoma.胰腺导管腺癌的蛋白质基因组学特征分析。
基于机器学习构建的损伤相关分子模式相关评分可识别出具有不同预后的胰腺腺癌亚型。
Oncol Lett. 2025 Mar 24;29(5):246. doi: 10.3892/ol.2025.14992. eCollection 2025 May.
4
Immune-related signature identifies IL1R2 as an immunological and prognostic biomarker in pancreatic cancer.免疫相关特征将白细胞介素1受体2鉴定为胰腺癌的免疫和预后生物标志物。
J Pancreatol. 2024 Jun;7(2):119-130. doi: 10.1097/JP9.0000000000000175. Epub 2024 Feb 22.
5
MicroRNAs in Pancreatic Cancer: Advances in Biomarker Discovery and Therapeutic Implications.胰腺癌细胞中的 microRNAs:生物标志物发现的新进展及其治疗意义。
Int J Mol Sci. 2024 Mar 31;25(7):3914. doi: 10.3390/ijms25073914.
6
Machine learning algorithm integrates bulk and single-cell transcriptome sequencing to reveal immune-related personalized therapy prediction features for pancreatic cancer.机器学习算法整合了批量和单细胞转录组测序,揭示了胰腺癌免疫相关的个性化治疗预测特征。
Aging (Albany NY). 2023 Dec 12;15(23):14109-14140. doi: 10.18632/aging.205293.
7
S100P as a potential biomarker for immunosuppressive microenvironment in pancreatic cancer: a bioinformatics analysis and in vitro study.S100P 作为胰腺癌免疫抑制微环境的潜在生物标志物:生物信息学分析和体外研究。
BMC Cancer. 2023 Oct 18;23(1):997. doi: 10.1186/s12885-023-11490-1.
Cell. 2021 Sep 16;184(19):5031-5052.e26. doi: 10.1016/j.cell.2021.08.023.
4
High-resolution Hi-C maps highlight multiscale 3D epigenome reprogramming during pancreatic cancer metastasis.高分辨率 Hi-C 图谱突出显示胰腺癌转移过程中的多尺度 3D 表观遗传重编程。
J Hematol Oncol. 2021 Aug 4;14(1):120. doi: 10.1186/s13045-021-01131-0.
5
Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response.免疫微环境的空间结构协调肿瘤免疫和治疗反应。
J Hematol Oncol. 2021 Jun 25;14(1):98. doi: 10.1186/s13045-021-01103-4.
6
Construction of a prognostic model with histone modification-related genes and identification of potential drugs in pancreatic cancer.构建基于组蛋白修饰相关基因的胰腺癌预后模型并鉴定潜在药物
Cancer Cell Int. 2021 Jun 5;21(1):291. doi: 10.1186/s12935-021-01928-6.
7
Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors.胰腺癌流行病学:了解生活方式和遗传风险因素的作用。
Nat Rev Gastroenterol Hepatol. 2021 Jul;18(7):493-502. doi: 10.1038/s41575-021-00457-x. Epub 2021 May 17.
8
S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.S100A14 促进胰腺癌的进展和吉西他滨耐药性。
Pancreatology. 2021 Apr;21(3):589-598. doi: 10.1016/j.pan.2021.01.011. Epub 2021 Jan 22.
9
Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer.类干细胞 CD8 T 细胞介导过继性细胞免疫疗法对人类癌症的反应。
Science. 2020 Dec 11;370(6522):1328-1334. doi: 10.1126/science.abb9847.
10
TISCH: a comprehensive web resource enabling interactive single-cell transcriptome visualization of tumor microenvironment.TISCH:一个全面的网络资源,可实现肿瘤微环境中交互式单细胞转录组可视化。
Nucleic Acids Res. 2021 Jan 8;49(D1):D1420-D1430. doi: 10.1093/nar/gkaa1020.